Astellas signs option and licensing agreement with Audax Biosciences worth up to $1.34bn for cancer therapy DAX-044
Astellas secures an exclusive global option to license Audax Biosciences' investigational IL-12 fusion therapy DAX-044
Astellas has entered an exclusive option and licensing agreement with Australian biotechnology company Audax Biosciences for DAX-044, an investigational immune-targeted IL-12 antibody-cytokine fusion therapy being developed for cancer treatment.
The agreement could be worth up to US$1.34bn excluding royalties, giving Astellas the opportunity to expand its immuno-oncology pipeline through a novel approach designed to direct IL-12 activity towards tumour-associated immune cells.
Field | Content |
Alert Type | Option and licensing agreement |
Article Type | Deals |
Companies | Astellas Pharma; Audax Biosciences |
Deal Type | Exclusive global option and licensing agreement |
Asset or Company | DAX-044 |
Therapy Area(s) | Oncology; immuno-oncology |
Technology or Modality | Immune-targeted interleukin-12 (IL-12) antibody-cytokine fusion therapy |
Deal Value | Up to US$1.34bn in potential transaction value, excluding royalties; individual payment components not specified in the supplied information |
Development Stage (if relevant) | Investigational development-stage therapy; precise clinical stage not established in the supplied information |
Geography | Japan; Australia; worldwide licensing rights |
What Happened | Astellas entered an exclusive option and licensing agreement with Australian biotechnology company Audax Biosciences covering DAX-044, an investigational immune-targeted IL-12 antibody-cytokine fusion therapy for immuno-oncology. The agreement grants Astellas an exclusive option to license the programme worldwide. |
Why It Matters | The agreement gives Astellas access to a differentiated immuno-oncology approach and represents a significant potential commercial opportunity for Australian biotechnology innovation. The transaction highlights continued pharmaceutical interest in therapies designed to improve the targeting of immune activation in cancer treatment. |
Supporting Context | IL-12 is an immune-signalling cytokine involved in stimulating anti-tumour immune responses. Targeted antibody-cytokine fusion approaches aim to concentrate immune activity in relevant biological environments while potentially limiting unwanted systemic exposure. |
Strategic Rationale (optional) | Astellas can evaluate a novel immune-targeted cytokine platform before exercising its global licensing option, while Audax gains a potential international development and commercialisation partner. |
Potential Impact (optional) | If successfully developed, DAX-044 could contribute to emerging immuno-oncology treatment strategies using targeted cytokine delivery. Clinical efficacy, safety and regulatory outcomes remain to be established. |
Key Takeaway | Astellas' agreement with Audax Biosciences provides an exclusive worldwide licensing option for DAX-044 in a potential US$1.34bn immuno-oncology transaction, excluding royalties. |
What to Watch (optional) | Astellas' decision on exercising the licensing option, further development milestones, emerging safety and efficacy data, and subsequent clinical progression of DAX-044. |
Primary Source | https://newsroom.astellas.com/2026-10-28-astellas-and-audax-biosciences-enter-exclusive-option-and-license-agreement-for-dax-044-a-novel-immune-targeted-il-12-antibody-cytokine-fusion-for-immuno-oncology |
Relevant Date | 28 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글